Company / Free Cash Flow per Share
Allogene Therapeutics, Inc. Free Cash Flow per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$0.71
FY2025
5-year range
-$1.44 / -$0.71
FY2021-FY2025
Trend
+50.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-1.44 to $-0.71 over the past 2 years.
Based on SEC 10-K filings.
-0.71 in FY2025.
Improved from $-1.44 to $-0.71 over the past 2 years.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow per share increased 50.3% year-over-year.
- Lowest free cash flow per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.71 | +50.3% |
| FY2024 | -$1.42 | +1.3% |
| FY2023 | -$1.44 | -76.7% |
| FY2022 | -$0.81 | +39.3% |
| FY2021 | -$1.34 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026